

Attorney Docket No. 1907.04-1

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

INVENTORS: Zavitz et al.)
Application No.: 10/663,407)
Filed: September 15, 2003) Group Art Unit: 1646
For: TSG101-GAG INTERACTION) Examiner: Unknown
AND USE THEREOF)

CERTIFICATE OF EXPRESS MAIL

"Express Mail" mailing label number: EV 329265033 US

Date of Deposit: November 15, 2004

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10 on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Stacey Stamper
Stacey L. Stamper

11/15/04
Date

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR § 1.97(b)(3)**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 222313-1450

Sir:


Attached is a list of documents on form PTO/SB/08A. Copies of U.S. patents are not being submitted pursuant to Pre-OG Notices <<http://www.uspto.gov/web/offices/pac/dapp/opla/preognotice/idswouscopies.htm>> (visited 9/15/2003). Copies of foreign patent documents and non-patent literature are enclosed pursuant to 37 C.F.R. § 1.98(a)(2).

It is requested that the Examiner consider these documents and officially make them of record in accordance with the provisions of 37 CFR § 1.97 and Section 609 of the MPEP. By submitting the listed documents, Applicants are in no way making any admission as to prior art status of the listed documents, but are instead submitting the listed documents for the sake of full disclosure under 37 CFR § 1.56.

To the best of the undersigned person's knowledge, this Information Disclosure Statement is being submitted in accordance with 37 CFR § 1.97(b)(3), before the mailing of a first Office action on merits.

It is believed that neither an extension of time, nor payment of any fee is required in connection with this communication. However, if an extension of time and corresponding extension fee, or any other fee is required, such an extension of time is hereby petitioned for and the Commissioner is authorized to charge any fees, or credit any overpayment, to Deposit Account No. 50-1627.

Respectfully submitted,




Jay Z. Zhang
Registration No. 44,003

Intellectual Property Department
Myriad Genetics, Inc.
(Customer No. 26698)
320 Wakara Way
Salt Lake City, UT 84108
Telephone: 801-584-3600
Fax: 801-883-3871

Date: November 15, 2004

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.



<p>Substitute for form 1449A/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p><i>(use as many sheets as necessary)</i></p> <p>Sheet 1 of 5</p>		Complete if Known	
		Application Number	10/663,407
		Filing Date	September 15, 2003
		First Named Inventor	Zavitz et al.
		Art Unit	1646
		Examiner Name	Unknown
Attorney Docket Number			
1907.04-1			

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

b Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

<p>Substitute for form 1449A/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(use as many sheets as necessary)</p>				Complete if Known	
				Application Number	10/663,407
				Filing Date	September 15, 2003
				First Named Inventor	Zavitz et al.
				Art Unit	1646
				Examiner Name	Unknown
Sheet	2	of	5	Attorney Docket Number	1907.04-1

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
		ACCOLA et al., "Efficient Particle Production by Minimal Gag Constructs Which Retain the Carboxy-Terminal Domain of Human Immunodeficiency Virus Type 1 Capsid-p2 and a Late Assembly Domain", <i>Journal of Virology</i> , June 2000, 74(12):5395-5402.			
		ALEXANDER et al., "Unusual Polymorphisms in Human Immunodeficiency Virus Type 1 Associated with Nonprogressive Infection", <i>Journal of Virology</i> , May 2000, 74(9):4361-4376.			
		BABST et al., "Mammalian Tumor Susceptibility Gene 101 (TSG101) and the Yeast Homologue, Vps23p, Both Function in Late Endosomal Trafficking", <i>Traffic</i> , 2000, 1:248-258.			
		BISHOP et al., "TSG101/Mammalian VPS23 and Mammalian VPS28 Interact Directly and Are Recruited to VPS4-induced Endosomes", <i>The Journal of Biological Chemistry</i> , April 13, 2001, 276(15):11735-11742.			
		BUTKIEWICZ et al., "Virus-Specific Cofactor Requirement and Chimeric Hepatitis C Virus/GB Virus B Nonstructural Protein 3" <i>Journal of Virology</i> , May 2000, 74(9):4291-4301.			
		CARTER, "Tsg101: HIV-1's ticket to ride", <i>Trends in Microbiology</i> , May 2002, 10(5):203-205.			
		CRAVEN et al., "Late Domain Function Identified in the Vesicular Stomatitis Virus M Protein by Use of Rhabdovirus-Retrovirus Chimeras", <i>Journal of Virology</i> , April 1999, 73(4):3359-3365.			
		CRUMPT et al., "Inhibition of the Interaction between Tyrosine-based Motifs and the Medium Chain Subunit of the AP-2 Adaptor Complex by Specific Tyrophostins", <i>The Journal of Biological Chemistry</i> , October 23, 1998, 273(43):28073-28077.			
		DEMIROV et al., "Overexpression of the N-Terminal domain of TSG101 inhibits HIV-1 budding by blocking late domain function", <i>PNAS</i> , January 22, 2002, 99(2):955-960.			
		DESAI et al., "Molecular cloning and primary nucleotide sequence analysis of a distinct human immunodeficiency virus isolate reveal significant divergence in its genomic sequences", <i>PNAS</i> , November 1986, 83(21):8380-8384.			
		DESCHAMBEAULT et al., "Polarized Human Immunodeficiency Virus Budding in Lymphocytes Involves a Tyrosine-Based Signal and Favors Cell-to-Cell Viral Transmission", <i>Journal of Virology</i> , June 1999, 73(6):5010-5017.			
		FARRAR et al., "Characterisation of a Series of Human Immunodeficiency Virus Isolates Derived Sequentially From a Single Patient", <i>Journal of Medical Virology</i> , 1991, 34:104-113.			
		GARNIER et al., "Identification of Retroviral Late Domains as Determinants of Particle Size", <i>Journal of Virology</i> , March 1999, 73(3):2309-2320.			
		GARRUS et al., "Tsg101 and the Vacuolar Protein Sorting Pathway Are Essential for HIV-1 Budding", <i>Cell</i> , October 5, 2001, 107:55-65.			

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known
Sheet	3	of	5	Attorney Docket Number
				1907.04-1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		HARTY et al., "A PPxY motif within the VP40 protein of Ebola virus interacts physically and functionally with a ubiquitin ligase: Implications for filovirus budding", <i>PNAS</i> , December 5, 2000, 97(25):13871-13876.	
		HARTY et al., "A Proline-Rich Motif within the Matrix Protein of Vesicular Stomatitis Virus and Rabies Virus Interacts with WW Domains of Cellular Proteins: Implications for Viral Budding", <i>Journal of Virology</i> , April 1999, 73(4):2921-2929.	
		HARVEY et al., "Nedd4-like proteins: an emerging family of ubiquitin-protein ligases implicated in diverse cellular functions", <i>Trends in Cell Biology</i> , May 1999, 9:166-169.	
		HEINRICHS et al., "In vivo analysis of the functional domains of the Drosophila splicing regulator RBP1", 1997, <i>PNAS</i> , 94:115-120.	
		HUANG et al., "p6 ^{Gag} Is Required for Particle Production from Full-Length Human Immunodeficiency Virus Type 1 Molecular Clones Expressing Protease", <i>Journal of Virology</i> , November 1995, 69(11):6810-6818.	
		JAYAKAR et al., "Mutations in the PPPY Motif of Vesicular Stomatitis Virus Matrix Protein Reduce Virus Budding by Inhibiting a Late Step in Virion Release", <i>Journal of Virology</i> , November 2000, 74(21):9818-9827.	
		LEVIN et al., "Inhibition of Early and Late Events of the HIV-1 Replication Cycle by Cytoplasmic Fab Intrabodies against the Matrix Protein, p17", <i>Molecular Medicine</i> , February 1997, 3(2):96-110.	
		LUBAN, "HIV-1 and Ebola virus: The getaway driver nabbed", <i>Nature Medicine</i> , December 2001, 7(12):1278:1280.	
		MARTIN-SERRANO et al., "HIV-1 and Ebola virus encode small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress", <i>Nature Medicine</i> , December 2001, 7(12):1313-1319.	
		MHASHILKAR et al., "Inhibition of HIV-1 Tat-mediated LTR transactivation and HIV-1 infection by anti-Tat single chain intrabodies", <i>The EMBO Journal</i> , 1995, 14(7):1542-1551.	
		MYERS et al., "Tsg101, an Inactive Homologue of Ubiquitin Ligase E2, Interacts Specifically with Human Immunodeficiency Virus Type 2 Gag Polyprotein and Results in Increased Levels of Unubiquitinated Gag", <i>Journal of Virology</i> , November 2002, 76(22):11226-11235.	
		NCBI Entrez Protein Database Accession No.: AAB38034, December 5, 1996.	
		NCBI Entrez Protein Database Accession No.: AAB83138, November 6, 1997.	
		NCBI Entrez Protein Database Accession No.: AAB83216, November 6, 1997.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

<p>Substitute for form 1449A/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(use as many sheets as necessary)</p>				Complete if Known	
				Application Number	10/663,407
				Filing Date	September 15, 2003
				First Named Inventor	Zavitz et al.
				Art Unit	1646
Examiner Name	Unknown				
Sheet	4	of	5	Attorney Docket Number	1907.04-1

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. ^{T²}			
		NCBI Entrez Protein Database Accession No.: AAB83821, November 6, 1997.			
		NCBI Entrez Protein Database Accession No.: AAD03232, January 6, 1999.			
		NCBI Entrez Protein Database Accession No.: AAD03240, January 6, 1999.			
		NCBI Entrez Protein Database Accession No.: AAD17020, June 1, 2001.			
		NCBI Entrez Protein Database Accession No.: AAF35354, February 23, 2000.			
		NCBI Entrez Protein Database Accession No.: CAB92786, September 20, 2000.			
		NCBI Entrez Protein Database Accession No.: P35962, July 15, 1998.			
		OTT et al., "Ubiquitin Is Covalently Attached to the p6 ^{Gag} Proteins of Human Immunodeficiency Virus Type 1 and Simian Immunodeficiency Virus and to the p12 ^{Gag} Protein of Moloney Murine Leukemia Virus", <i>Journal of Virology</i> , April 1998, 72(4):2962-2968.			
		PARENT et al., "Positionally Independent and Exchangeable Late Budding Functions of the Rous Sarcoma Virus and Human Immunodeficiency Virus Gag Proteins", <i>Journal of Virology</i> , September 1995, 69(9):5455-5460.			
		PATNAIK et al., "Ubiquitin is part of the retrovirus budding machinery", <i>PNAS</i> , November 21, 2000, 97(24):13069-13074.			
		PORNILLOS et al., Structure and functional interactions of the Tsg101 UEV domain", <i>The EMBO Journal</i> , 2002, 21(10):2397-2406.			
		PORNILLOS et al., "Structure of the Tsg101 UEV domain in complex with the PTAP motif of the HIV-1 p6 protein", <i>Nature Structural Biology</i> , November 2002, 9(11):812-817.			
		PUFFER et al., "Equine Infectious Anemia Virus Gag Polyprotein Late Domain Specifically Recruits Cellular AP-2 Adapter Protein Complexes during Virion Assembly", <i>Journal of Virology</i> , December 1998, 72(12):10218-10221.			
		PUFFER et al., "Equine Infectious Anemia Virus Utilizes a YXXL Motif within the Late Assembly Domain of the Gag p9 Protein", <i>Journal of Virology</i> , September 1997, 71(9):6541-6546.			
		ROSSI, "Therapeutic applications of catalytic antisense RNAs (ribozymes)", <i>CIBA Foundation Symposium</i> , 1997, 209:195-206.			
		SAVARINO et al., "The Biochemistry of Gene Therapy for AIDS", <i>Clin. Chem. Lab. Med.</i> , 1998, 36(4):205-210.			

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<p>Substitute for form 1449A/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(use as many sheets as necessary)</p>				Complete if Known	
				Application Number	10/663,407
				Filing Date	September 15, 2003
				First Named Inventor	Zavitz et al.
				Art Unit	1646
				Examiner Name	Unknown
Sheet	5	of	5	Attorney Docket Number	1907.04-1

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
		SCHUBERT et al., "Proteasome inhibition interferes with Gag polyprotein processing, release, and maturation of HIV-1 and HIV-2", <i>PNAS</i> , November 21, 2000, 97(24):13057-13062.			
		SORKINA et al., "Clathrin, adaptors and eps15 in endosomes containing activated epidermal growth factor receptors", <i>Journal of Cell Science</i> , 1999, 112:317-327.			
		STRACK et al., "A role for ubiquitin ligase recruitment in retrovirus release", <i>PNAS</i> , November 21, 2000, 97(24):13063-13068.			
		VERKHIVKER, "Towards understanding the mechanisms of molecular recognition by computer simulations of ligand-protein interactions", <i>Journal of Molecular Recognition</i> , 1999, 12:371-389.			
		VERPLANK et al., "Tsg101, a homologue of ubiquitin-conjugating (E2) enzymes, binds the L domain in HIV type 1 Pr55Gag", <i>PNAS</i> , July 3, 2001, 98(14):7724-7729.			
		VOGTL., "Ubiquitin in retrovirus assembly: Actor or bystander?", <i>PNAS</i> , November 21, 2000, 97(24):12945-12947.			
		WHITTLE et al., "Protein Structure-Based Drug Design", <i>Annu. Rev. Biophys. Biomol. Struct.</i> , 1994, 23:349-375.			
		YASUDA et al., "A Proline-Rich Motif (PPPY) in the Gag Polyprotein of Mason-Pfizer Monkey Virus Plays a Maturation-Independent Role in Virion Release", <i>Journal of Virology</i> , May 1998, 72(5):4095-4103.			
		YUAN et al., "Infectivity of Moloney Murine Leukemia Virus Defective in Late Assembly Events Is Restored by Late Assembly Domains of Other Retroviruses", <i>Journal of Virology</i> , August 2000, 74(16):7250-7260.			
		YUAN et al., "Mutations altering the Moloney murine leukemia virus p12 Gag protein affect virion production and early events of the virus life cycle", <i>The EMBO Journal</i> , 1999, 18(17):4700-4710.			
		ZHANG et al., "Drug Resistance during Indinavir Therapy Is Caused by Mutations in the Protease Gene and in Its Gag Substrate Cleavage Sites", <i>Journal of Virology</i> , September 1997, 71(9):6662-6670.			

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.